Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19 | Zendy

Asma Tariq | Zendy; Rana Muhammad Mateen | Zendy; Muhammad Sohail Afzal | Zendy; M. Saleem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19

Author(s) -

Asma Tariq,

Rana Muhammad Mateen,

Muhammad Sohail Afzal,

M. Saleem

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.06.063

Subject(s) - protease , paromomycin , coronavirus , drug repositioning , drug , pharmacology , virology , in silico , binding domain , biology , drug discovery , chemistry , binding site , biochemistry , medicine , infectious disease (medical specialty) , covid-19 , antibiotics , enzyme , disease , aminoglycoside , pathology , gene

Current study concluded that Paromomycin is an effective dual targeting drug against coronavirus, as it binds not only to the protease domain of the virion but also with the spike domain with high stability. Furthermore, none of the anti-malarial drugs showed strong binding affinity for either protease or receptor binding domain (RBD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research